Bionano Genomics (BNGO) Non-Current Deffered Revenue (2017 - 2026)
Bionano Genomics (BNGO) posted Non-Current Deffered Revenue of $143000.0 for Q1 2026, down 42.57% sequentially from $249000.0 in Q4 2025, and down 51.03% YoY from $292000.0 in Q1 2025.
Bionano Genomics (BNGO) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Bionano Genomics has reported Non-Current Deffered Revenue for 10 years, with the latest figure at $143000.0 in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 51.03% year-over-year to $143000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $143000.0 (down 51.03% YoY) and the FY2025 annual result came in at $249000.0, down 6.74% from the prior year.
- Non-Current Deffered Revenue slipped to $143000.0 in Q1 2026 per BNGO's latest filing, from $249000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $292000.0 in Q1 2025 and troughed at $127000.0 in Q4 2022.
- A 5-year average of $196647.1 and a median of $192000.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2025 and 2026: Non-Current Deffered Revenue surged 111.59% in 2025, then tumbled 51.03% in 2026.
- Over 5 years, Non-Current Deffered Revenue stood at $127000.0 in 2022, then gained by 21.26% to $154000.0 in 2023, then soared by 73.38% to $267000.0 in 2024, then retreated by 6.74% to $249000.0 in 2025, then tumbled by 42.57% to $143000.0 in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $143000.0, $249000.0, and $192000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | - |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | - |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 170.95 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | - |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 13.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | - |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 208.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | - |
| 10 | Bionano Genomics | 13.74 Mn | 3.81 Mn | 4.31 Mn | 118,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 118,000.00 |
| Mar 31, 2026 | 143,000.00 |
| Dec 31, 2025 | 249,000.00 |
| Sep 30, 2025 | 192,000.00 |
| Jun 30, 2025 | 243,000.00 |
| Mar 31, 2025 | 292,000.00 |
| Dec 31, 2024 | 267,000.00 |
| Sep 30, 2024 | 263,000.00 |
| Jun 30, 2024 | 272,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Dec 31, 2023 | 154,000.00 |
| Sep 30, 2023 | 151,000.00 |
| Jun 30, 2023 | 186,000.00 |
| Mar 31, 2023 | 194,000.00 |
| Dec 31, 2022 | 127,000.00 |
| Sep 30, 2022 | 136,000.00 |
| Jun 30, 2022 | 203,000.00 |
| Mar 31, 2022 | 133,000.00 |
| Dec 31, 2021 | 146,000.00 |
| Sep 30, 2021 | 158,000.00 |